



CLINICAL EVALUATION OF THE EFFICACY OF
IMAGE MD RESTORING POWER C SERUM
SUMMARY PROTOCOL Nº: 0207-21A-11E
January, 2022

IMAGE SKINCARE enlisted an independent clinical testing laboratory to conduct a 12-week study to objectively analyze the effectiveness of a skin treatment product to:

- Improve fine lines & wrinkles
- Diminish the appearance of age spots and pigmentation and brighten the skin
- Even skin tone & texture
- Protect the skin from sun damage and pollution
- Defend against photodamage and reduce the potential for pigmentation and redness
- Lock hydration into the skin
- Help to restore firmness, smoothness, and elasticity

TEST PRODUCT

Restoring Power-C serum

STUDY SUBJECT INCLUSION CRITERIA:

- a. Individuals who, at baseline, are free of any dermatological or systemic disorder, which would interfere with the results, at the discretion of the Investigator.
- b. Individuals in good general health.
- c. Individuals who will read, understand and sign an informed consent document.
- d. Individuals who will be able to cooperate with the Investigator and research staff, have the test product applied according to the protocol and complete the full course of the study.
- e. Individuals who have not participated in any study involving the same test site (face) for the past 15 days.
- f. Individuals who will agree to refrain from using personal care products (e.g., cleansers, lotions, creams, serums) for the washout period and duration of the study, with the exception of those provided by the clinical testing facility.
- g. Individuals who agree to continue usage of their current cosmetics (e.g., foundation, blush) if applicable, so long as products contain no anti-aging properties, and the subjects have a safe usage history for the duration of the study. Subjects will be instructed not to wear any form of cosmetics on the study visit days.
- h. Individuals who are willing to bring their cosmetic products to the clinical testing facility for inspection by facility staff member.
- i. Individuals with visible mixture on skin types under the Fitzpatrick classification.
- j. Individuals who agree not to sunbath/tan and agree to avoid sun exposure as much as possible for the duration of the study.



CLINICAL EVALUATION OF THE EFFICACY OF
IMAGE MD RESTORING POWER C SERUM
SUMMARY PROTOCOL N°: 0207-21A-11E
January, 2022

STUDY SUBJECT EXCLUSION CRITERIA:

- a. Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation.
- b. Individuals with an active (flaring) disease or chronic skin allergies (atopic dermatitis/eczema), or had recently treated skin cancer (within the last 12 months).
- c. Individuals with damaged skin at or in close proximity to test sites (e.g., sunburn, tattoos, scars, excessive hair, non-removable piercings, or other disfigurements).
- d. Individuals who have any history, which, in the Investigator's opinion, indicates the potential for harm to the subject or could place the validity of the study in jeopardy.
- e. Individuals who indicate that they are pregnant, planning a pregnancy or nursing.
- f. Individuals who use injectable insulin to control their diabetes.
- g. Individuals who have had any medical procedure, such as laser resurfacing, or plastic surgery to the test sites within the last 12 months (including Botox[®], Restylane[®], or other fillers).
- h. Individuals who are currently using or during the last 3 months have used, Retin A, or other Rx/OTC Retinyl A, or other astringent derived products or alpha hydroxyl acid treatments for photo-aging and fine lines/wrinkles.
- i. Individuals who have a known history of hypersensitivity to any cosmetics, personal care products, and/or fragrances.

STUDY USE INSTRUCTIONS

Shake well before use. Apply 3 5 drops to clean skin every morning



CLINICAL EVALUATION OF THE EFFICACY OF
IMAGE MD RESTORING POWER C SERUM
SUMMARY PROTOCOL N°: 0207-21A-11E
January, 2022

SUMMARY OF RESULTS

IMAGE MD RESTORING POWER-C SERUM provided the following statistically significant improvements after weeks of use of the test product:

In 1 week:

10% improvement in the skin tone and pigmentation of facial
97% subjects demonstrated an improvement in the skin tone and pigmentation of facial

In 4 weeks:

24% improvement in the skin tone and pigmentation of facial
97% subjects demonstrated an improvement in the skin tone and pigmentation of facial

In 12 weeks:

36% improvement in the skin tone and pigmentation of facial
100% subjects demonstrated an improvement in the skin tone and pigmentation of facial

In all instance decreased the values of the TEWL “transepidermal water loss” means an increase in protect the skin from damage and pollution and lock hydration into the skin.

In 1 week:

16% decreased in TEWL trans epidermal water loss
100% subjects demonstrated an improvement on the skin barrier.

In 4 weeks:

19% decreased in TEWL trans epidermal water loss
100% subjects demonstrated an improvement on the skin barrier

In 4 weeks:

16% improvement in the fine lines and wrinkles of facial skin
100% subjects demonstrated an improvement in the fine lines and wrinkles of facial skin.

In 12 weeks:

24% improvement in the fine lines and wrinkles of facial skin.
100% subjects demonstrated an improvement in the fine lines and wrinkles of facial skin.

In 4 weeks:

18% improvement in the smoothness of facial skin.
100% subjects demonstrated an improvement in the smoothness of facial skin.



CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

In 12 weeks:

22% improvement in the smoothness of facial skin

100% subjects demonstrated an improvement in the smoothness of facial skin

In 4 weeks:

24% improvement in the firmness of facial skin

100% subjects demonstrated an improvement in the firmness of facial skin.

In 12 weeks:

39% improvement in the firmness of facial skin

100% subjects demonstrated an improvement in the firmness of facial skin

In 4 weeks:

13% improvement in the elasticity of facial skin

100% subjects demonstrated an improvement in the elasticity of facial skin.

In 12 weeks:

20% improvement in the elasticity of facial skin

100% subjects demonstrated an improvement in the elasticity of facial skin

INSTRUMENTAL EVALUATION

Under conditions of the study a total of 35 healthy male and female subjects, 21-55years of age, completed the clinical study evaluating the efficacy of “**IMAGE MD RESTORING POWER-C SERUM**”.

A. Photodamage -Tone & Pigmentation of Facial Skin by Chromameter Minolta 400


Improvement - Photodamage - Tone & Pigmentation of Facial Skin			
Initial	1-Week	4-Weeks	12-Weeks
16.83 ^a	18.56 ^b	20.88 ^c	22.96 ^d
% Improvement:	10%	24%	36%
Vol. with improvement	97%	97%	100%

Parameters with * correspond to those in which treatment resulted in significant changes for an α -risk 0.05 and β -risk 0.2, according to STUDENT T-TEST OF PAIRED SAMPLES. Mean values with different letters are significantly different according to the test.



CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

B. Transepidermal water loss by Tewameter 300®
 The graphic evidence a significant decrease TEWL



* A decrease in the values of the transepidermal water loss means increased skin protection from damage and pollution and lock of skin's hydration.

C. Fine lines and wrinkles of facial skin by Visioscan® VC 20plus and Sels

The fine lines and wrinkles of facial skin improvement can be summarized in the following charts:

Improvement - Lines & Wrinkles of Facial Skin		
Initial	4-Weeks	12-Weeks
82.89 ^a	71.55 ^b	67.04 ^c
% Improvement:	16%	24%
Vol. with improvement	100%	100%

Parameters with * correspond to those in which treatment resulted in significant changes for an α -risk 0.05 and β -risk 0.2, according to STUDENT T-TEST OF PAIRED SAMPLES. Mean values with different letters are significantly different according to the test



CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL N°: 0207-21A-11E
 January, 2022

D. Smoothness of facial skin by Visioscan®VC 20plus and Sels

The smoothness of skin texture of facial skin improvement can be summarized in the following charts:

Improvement - Smoothness of Facial Skin		
Initial	4-Weeks	12-Weeks
274.50 ^a	323.10 ^b	334.05 ^c
% Improvement:	18%	22%
Vol. with improvement	100%	100%

Parameters with * correspond to those in which treatment resulted in significant changes for an α -risk 0.05 and β -risk 0.2, according to STUDENT T-TEST OF PAIRED SAMPLES. Mean values with different letters are significantly different according to the test.

E. Firmness of facial skin by Cutometer®

The firmness of facial skin improvement can be summarized in the following charts:

Initial	4-Weeks	12-Weeks
0.08 ^a	0.06 ^b	0.05 ^c
% Improvement:	24%	39%
Vol. with improvement	100%	100%

Parameters with * correspond to those in which treatment resulted in significant changes for an α -risk 0.05 and β -risk 0.2, according to STUDENT T-TEST OF PAIRED SAMPLES. Mean values with different letters are significantly different according to the test.



CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

F. Elasticity of facial skin by Cutometer®

The elasticity of facial skin improvement can be summarized in the following charts:

Improvement - Elasticity of Facial Skin		
Initial	4-Weeks	12-Weeks
0.74 ^a	0.83 ^b	0.89 ^c
% Improvement:	13%	20%
Vol. with improvement	100%	100%

Parameters with * correspond to those in which treatment resulted in significant changes for an α -risk 0.05 and β -risk 0.2, according to STUDENT T-TEST OF PAIRED SAMPLES. Mean values with different letters are significantly different according to the test.

VOLUNTEER'S PERCEPTION

Post Treatment Self-assessment questionnaire

At this instance the panelist also answered some questionnaires assigning scores to the answers according to a scale from 0 to 4, whose interpretation can be summarized in the following chart:

0	1	2	3	4
<i>Very Much Disagree</i>	<i>Disagree</i>	<i>Neutral</i>	<i>Agree</i>	<i>Very Much Agree</i>



**CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022**

Question	Time	% of agreement
I like the texture.	1-Week	80%
	4-Weeks	89%
	12-Weeks	89%
Has a pleasant scent.	1-Week	51%
	4-Weeks	63%
	12-Weeks	69%
Feels good on the skin.	1-Week	77%
	4-Weeks	91%
	12-Weeks	91%
Skin feels instantly moisturize.	1-Week	80%
	4-Weeks	94%
	12-Weeks	94%
Skin feels nourished.	1-Week	72%
	4-Weeks	83%
	12-Weeks	83%
This product absorbs easily without leaving a residue.	1-Week	72%
	4-Weeks	72%
	12-Weeks	72%
Leaves skin looking more luminous and radiant.	1-Week	74%
	4-Weeks	83%
	12-Weeks	83%
Brightens complexion.	1-Week	71%
	4-Weeks	83%
	12-Weeks	83%
Skin feels soft.	1-Week	77%
	4-Weeks	98%
	12-Weeks	98%



CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

Skin looks dewy.	1-Week	83%
	4-Weeks	91%
	12-Weeks	91%
Provides essential hydration.	1-Week	71%
	4-Weeks	80%
	12-Weeks	89%
Skin appears brighter.	1-Week	80%
	4-Weeks	92%
	12-Weeks	89%
Helps to restore firmness & elasticity.	1-Week	55%
	4-Weeks	72%
	12-Weeks	94%
Evens skin tone and texture.	1-Week	49%
	4-Weeks	69%
	12-Weeks	77%
Skin looks smother.	1-Week	69%
	4-Weeks	72%
	12-Weeks	94%
Skin looks rejuvenated.	1-Week	60%
	4-Weeks	95%
	12-Weeks	91%
Skin looks more youthful.	1-Week	57%
	4-Weeks	83%
	12-Weeks	89%
Promotes a firmer-looking skin.	1-Week	60%
	4-Weeks	77%
	12-Weeks	89%
Helps diminish skin's redness intensity.	4-Weeks	54%
	12-Weeks	69%
Helps diminish skin's pigmentation.	4-Weeks	58%
	12-Weeks	71%



CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

Improves skin color variation.	4-Weeks	63%
	12-Weeks	78%
Promotes a more even, uniform skin tone.	4-Weeks	69%
	12-Weeks	86%
Helps fade dark spots.	4-Weeks	63%
	12-Weeks	80%
Improve the appearance of fine lines & wrinkles.	12-Weeks	66%
Diminish the appearance of age spots and pigmentation.	12-Weeks	71%
Improves skin's overall appearance.	12-Weeks	97%
I'm satisfied with the appearance of my skin.	12-Weeks	77%
Would you purchase this product?	12-Weeks	94%
I prefer this product vs. the one I used before.	12-Weeks	97%
Would you recommend this product to a friend?	12-Weeks	97%

In addition to the previous questionnaires, it was implemented a final question in order to rate the product as a whole. The results can be summarized in the following table:

How would you rate this product?				
1 = Poor	2 = Fair	3 = Good	4 = Very Good	5 = Excellent
0%	0%	45%	49%	6%

APPENDIX A

A. Photodamage -Tone & Pigmentation of Facial Skin by Chromameter Minolta 400

Instrumental measurements of the panelists skin tone and pigmentation of facial skin were performed by a CHROMAMETER MINOLTA , using parameters LL* and bb* to calculate the ITA angle, in order to evaluate the improvement of skin tone and pigmentation of facial skin, and if it defends against photodamage. These measurements were performed at the beginning of the treatment, one, four and twelve weeks after its application, after which the study of the variation of the mean value of those numbers was conducted by a STUDENT T EST OF PAIRED SAMPLES , with an α risk 0.05 and β risk 0.2. In this case, the relevant parameter is the ITA angle, and it is desirable that numbers should increase


Quantitative criteria can be summarized in the following chart:

Parameter	Time	Mean	SD	Min	Max	Sample Size n	Median
L^*	Initial	55.65	7.88	32.55	64.36	35	57.65
	1-Week	56.37	7.83	33.41	64.81	35	58.37
	4-Weeks	56.92	7.30	34.84	65.44	35	58.76
	12-Weeks	57.77	6.92	35.15	65.51	35	58.99

Parameter	Time	Mean	SD	Min	Max	Sample Size n	Median
b^*	Initial	16.90	3.19	8.62	22.64	35	17.73
	1-Week	17.08	3.37	8.16	22.65	35	17.51
	4-Weeks	16.82	3.23	9.10	22.95	35	17.16
	12-Weeks	16.94	3.35	9.11	22.90	35	17.22

Parameter	Time	Mean	SD	Min	Max	Sample Size n	Median
ITA	Initial	16.83	26.55	-63.02	55.85	35	22.18
	1-Week	18.56	26.51	-60.72	56.47	35	23.65
	4-Weeks	20.88	24.82	-56.81	57.50	35	24.49
	12-Weeks	22.96	23.83	-50.57	58.85	35	26.09

Graphically, it can be observed that the numbers for ITA increase:




*The significant decrease in ITA ° is correlated to a dark skin color tone.

B. Transepidermal water loss by Tewameter 300®

The graphic evidence a significant decrease TEWL

Transepidermal Water Loss / Moisture loss

This study was conducted at a temperature 22°C and 52% H



Reference table

TEWL-values g/h/m²

0-10	very healthy condition
10-15	healthy condition
15-25	NORMAL condition
25-30	strained skin
above 30	critical condition

C. Fine lines and wrinkles of facial skin by Visioscan® VC 20plus and Sels

Instrumental measurements of the panelist’s fine lines and wrinkles of facial skin were performed by a VISIOSCAN VC20PLUS WITH SELS, using parameter *Sew*, in order to evaluate the improvement of the fine lines and wrinkles of facial skin. These measurements were performed at the beginning of the treatment, four and twelve weeks after its application, after which the study of the variation of the mean value of those numbers was conducted by a STUDENT T-TEST OF PAIRED SAMPLES, with an α -risk 0.05 and β -risk 0.2. For *Sew*, it is desirable that numbers should decrease.


Quantitative criteria can be summarized in the following chart:



CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

Parameter	Time	Mean	SD	Min	Max	Sample Size n	Median
Sew	Initial	82.89	27.97	32.84	133.90	35	85.64
	4-Weeks	71.55	24.51	28.31	115.14	35	69.18
	12-Weeks	67.04	22.86	25.25	109.87	35	64.23

Graphically, it can be observed that the numbers for Sew decrease:




D. Smoothness of facial skin by Visioscan®VC 20plusand Sels

Instrumental measurements of the panelists smoothness of facial skin were performed by a VISIOSCAN VC20PLUS WITH SELS, using parameter *Sesm*, in order to evaluate the improvement of the smoothness of facial skin. These measurements were performed at the beginning of the treatment, four and twelve weeks after its application, after which the study of the variation of the mean value of those numbers was conducted by a STUDENT T-TEST OF PAIRED SAMPLES, with an α -risk 0.05 and β -risk 0.2. For *Sesm*, it is desirable that numbers should increase.

Quantitative criteria can be summarized in the following chart:

Parameter	Time	Mean	SD	Min	Max	Sample Size n	Median
Sesm	Initial	274.50	97.42	92.36	509.64	35	266.54
	4-Weeks	323.10	114.93	106.42	578.94	35	307.77
	12-Weeks	334.05	115.94	110.58	595.24	35	315.48





CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022


E. Firmness of facial skin by Cutometer®

Instrumental measurements of the panelists firmness of facial skin were performed by a CUTOMETER, using parameter *R0*, in order to evaluate the improvement of the firmness of facial skin. These measurements were performed at the beginning of the treatment, four and twelve weeks after its application, after which the study of the variation of the mean value of those numbers was conducted by a STUDENT T-TEST OF PAIRED SAMPLES, with an α -risk 0.05 and β -risk 0.2. For *R0*, it is desirable that numbers should decrease

Quantitative criteria can be summarized in the following chart:

Parameter	Time	Mean	SD	Min	Max	Sample Size n	Median
<i>R0</i>	Initial	0.08	0.02	0.03	0.11	35	0.08
	4-Weeks	0.06	0.02	0.03	0.09	35	0.06
	12-Weeks	0.05	0.02	0.02	0.08	35	0.05

Graphically, it can be observed that the numbers for *R0* decrease:





CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022


F. Elasticity of facial skin by Cutometer®

Instrumental measurements of the panelists elasticity of facial skin were performed by a CUTOMETER, using parameter *R7*, in order to evaluate the improvement of the elasticity of facial skin. These measurements were performed at the beginning of the treatment, four and twelve weeks after its application, after which the study of the variation of the mean value of those numbers was conducted by a STUDENT T-TEST OF PAIRED SAMPLES, with an α -risk 0.05 and β -risk 0.2. For *R7* it is desirable that numbers should increase.

Quantitative criteria can be summarized in the following chart:

Parameter	Time	Mean	SD	Min	Max	Sample Size n	Median
<i>R7</i>	Initial	0.74	0.05	0.64	0.84	35	0.73
	4-Weeks	0.83	0.05	0.76	0.93	35	0.83
	12-Weeks	0.89	0.05	0.79	0.98	35	0.89

Graphically, it can be observed that the numbers for *R7* increase:



CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

APPENDIX B

A) Skin Photodamage - tone and pigmentation of facial skin by Chromameter Minolta 400®

	t= 0				t= 1 weeks				t= 4 weeks				t=12 weeks			
	L*	a*	b*	ITA	L*	a*	b*	ITA	L*	a*	b*	ITA	L*	a*	b*	ITA
1	55.6	13.46	17.73	17.53	57.07	11.87	19.98	19.49	57.33	11.69	16.95	23.39	57.47	11.44	16.97	23.76
2	62.45	11.57	16.51	37.02	62.88	9.9	16.72	37.61	64.44	9.22	17.19	40.03	65.24	12.13	17.88	40.44
3	38.96	10.73	15.53	-35.41	39.39	10.48	15.33	-34.69	39.76	10.12	15.23	-33.92	42.31	11.4	15.72	-26.07
4	60.73	11	18.98	29.48	61.06	10.65	18.47	30.91	61.82	9.70	18.63	32.39	62.83	8.52	19.39	33.49
5	55.31	11.67	18.91	15.68	56.1	11	18.86	17.92	56.44	10.91	18.18	19.51	56.98	12.1	18.22	20.96
6	32.55	9.83	9.55	-61.31	33.41	8.89	9.95	-59.05	34.84	8.39	12.41	-50.70	35.15	10.7	12.21	-50.57
7	62.5	13.24	14.74	40.30	63.19	12.47	15.09	41.16	63.86	12.73	15.13	42.49	64.9	12.55	15.44	43.98
8	57.45	12.22	15.26	26.02	57.95	12.11	15.39	27.32	59.18	11.24	14.69	32.00	61.04	12.3	16	34.61
9	54.22	13.49	17.91	13.26	55.27	13.3	18.68	15.75	53.02	13.10	18.18	9.43	55.4	13.22	18.89	15.95
10	59.09	15.31	13.47	34.01	59.95	15.3	14.26	34.91	59.01	15.30	14.60	31.68	60.49	14.03	14.48	35.92
11	55.4	13.14	18.9	15.95	55.79	13.11	17.99	17.84	56.55	13.09	19.20	18.84	57.47	11.95	19.66	20.80
12	64.02	9.29	13.86	45.33	64.81	8.74	13.16	48.38	65.44	8.77	13.70	48.42	65.51	17.01	12.19	51.83
13	60.79	8.75	20.34	27.95	61.19	8.75	20.1	29.11	61.78	8.54	19.71	30.87	62.21	8.54	19.66	31.84
14	54.2	10.77	20.77	11.43	55.46	10.64	22.65	13.55	56.26	10.02	21.68	16.11	56.35	10.88	21.25	16.64
15	60.23	8.87	18.13	29.43	61.15	8.3	18.51	31.06	61.46	9.40	17.35	33.45	62.12	9.58	16.22	36.77
16	58.05	12.85	20.77	21.19	58.58	12.06	20.7	22.51	58.31	12.44	18.89	23.75	58.74	12.22	18.75	24.99
17	55.9	17.01	16.34	19.85	57.06	16.27	17.89	21.54	57.07	11.73	17.16	22.39	57.22	11.74	17.26	22.70

CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

	t= 0				t= 1 weeks				t= 4 weeks				t=12 weeks			
	L*	a*	b*	ITA	L*	a*	b*	ITA	L*	a*	b*	ITA	L*	a*	b*	ITA
18	55.54	18.14	15.91	19.20	55.77	18.12	14.16	22.17	56.48	13.23	15.32	22.93	56.79	12.34	15.41	23.78
19	58.23	10.44	16.89	25.98	59.11	10.18	15.92	29.78	59.11	10.61	15.90	29.81	60.1	10.57	16.01	32.25
20	60.62	10.4	18.29	30.14	61.54	10.33	18.99	31.29	61.19	10.04	17.86	32.07	61.67	10.22	17.22	34.13
21	64.36	9.74	9.74	55.85	64.58	9.71	9.66	56.47	64.99	9.71	9.55	57.50	65.07	9.45	9.11	58.85
22	51.07	17.02	18.8	3.26	51.38	15.54	20.67	3.82	51.37	15.20	18.90	4.15	52.07	15.22	19.1	6.19
23	59.04	13.51	17.97	26.71	59.99	12.06	17.51	29.71	59.98	11.87	16.99	30.43	60.55	13.59	17.85	30.58
24	62.08	9.23	16.37	36.42	62.83	9.46	16.67	37.58	63.09	9.82	16.54	38.36	63.88	9.44	17.15	38.98
25	53.53	9.66	20.93	9.57	54.04	9.92	20.9	10.94	54.25	9.26	20.15	11.91	54.89	9.27	21.22	12.98
26	56.68	11.86	22.64	16.44	57.33	10.76	22.05	18.39	57.89	10.89	21.89	19.82	57.94	10.62	21.96	19.88
27	39.96	11.43	15.53	-32.88	39.39	11.40	16.99	-31.98	50.67	11.59	22.95	1.67	50.68	11.56	22.9	1.70
28	62.69	12.28	14.02	42.15	63.55	12.15	14.77	42.53	62.51	11.17	10.90	48.93	62.69	15.54	10.3	50.94
29	57.65	12.58	18.45	22.52	58.37	12.46	19.11	23.65	58.76	12.21	19.23	24.49	59.84	13.21	19.27	27.05
30	57.96	11.60	19.52	22.18	58.59	11.69	19.24	24.06	58.90	11.59	18.22	26.03	58.99	11.96	18.36	26.09
31	53.28	12.47	19.29	9.65	54.03	12.41	20.43	11.16	52.03	12.14	20.25	5.72	54.89	13.66	19.81	13.87
32	55.45	11.40	17.81	17.01	55.80	11.20	16.80	19.05	55.11	11.10	16.64	17.07	55.61	11.24	16.89	18.37
33	60.01	11.96	16.41	31.38	61.08	11.97	16.78	33.44	62.15	11.42	13.45	42.09	62.98	12.57	14.29	42.25
34	59.04	16.61	16.52	28.69	59.86	16.22	15.26	32.87	61.03	15.93	16.08	34.45	61.88	14.82	16.65	35.51
35	33.07	7.95	8.62	-63.02	35.45	7.88	8.16	-60.72	36.09	7.88	9.10	-56.81	39.89	7.54	9.11	-47.98



CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

B. Transepidermal water loss by Tewameter 300®

	TWM		
	BASAL	t=1 weeks	t=4 weeks
1	12.5	10.6	10.6
2	10.3	9.6	11.7
3	13.3	12.3	9.3
4	12.1	11.4	13.1
5	46.2	23.6	14.6
6	10.6	5.9	6.8
7	16.8	8.8	9.4
8	8.1	8	9.4
9	10.2	9.3	10.5
10	13.6	13.4	13.3
11	13.5	12.4	14.1
12	10.7	7.6	10.5
13	13.4	12.6	13.7
14	14.4	13	13.7
15	12.2	11.3	11.8
16	15.4	14.8	14.5
17	14.4	13.5	14

	TWM		
	BASAL	t=1 weeks	t=4 weeks
18	12.9	11.8	11.2
19	10	8.9	9.3
20	13.3	12.2	11.2
21	11.4	11.2	10.2
22	16.2	10.7	11.5
23	13.5	12.9	11.6
24	15.6	15.1	12.3
25	14.6	13.9	12.9
26	12.3	10.6	10.3
27	12	11.5	11.3
28	14.3	10.2	13.9
29	15.2	11.5	11.1
30	13.7	12.9	13
31	12.5	9.6	10.3
32	15.9	21.8	13.4
33	31.6	16.4	13.4
34	14.8	14.3	13.3
35	12.4	12.2	11.4

CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL N°: 0207-21A-11E
 January, 2022

C) Fine Lines & Wrinkles of Facial Skin by Visioscan® VC 20plus and Sels

	Sew		
	t=0	t=4 W	t=12 W
1	74.12	67.18	62.57
2	59.8	52.32	50.02
3	32.84	28.91	26.01
4	118.91	104.36	89.8
5	111.43	100.06	94.71
6	33.04	28.31	25.25
7	65.43	53.39	53.1
8	108.76	97.06	88.69
9	107.76	91.25	85.07
10	47.4	41.33	37.91
11	78.32	69.18	63.39
12	101.38	87.74	83.47
13	48.27	40.19	39.52
14	55.36	45.5	44.89
15	80.91	64.1	61.59
16	59.57	53.01	45.09
17	69.54	60.27	58.34

	Sew		
	t=0	t=4 W	t=12 W
18	85.64	68.34	64.23
19	80.02	63.29	64.74
20	109.72	93.66	88.08
21	133.9	115.14	109.87
22	41.36	34.63	31.18
23	131.9	107.81	102.13
24	86.33	73.47	62.34
25	71.32	61.77	60.21
26	96.56	80.05	77.31
27	37.16	33.23	30.02
28	98.01	94.01	90.01
29	90.78	80.07	76.51
30	95.07	82.1	76.78
31	66.65	58.07	56.57
32	101.27	90.08	85.11
33	119.65	103.36	93.68
34	104.06	90.96	84.78
35	98.95	90.01	83.42

CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

D) Smoothness of facial skin by Visioscan® VC 20plus and Sels

	Sesm		
	t=0	t=4 W	t=12 W
1	216.88	256.46	269.57
2	226.16	262.43	273.24
3	128.87	147.78	154.62
4	223.94	259.72	261.22
5	412.18	466.46	489.52
6	92.36	106.42	110.58
7	269.59	309.37	315.48
8	387.5	500.72	509.79
9	327.37	398.66	398.97
10	164.85	202.33	246.86
11	195.59	229.32	266.76
12	255.51	299.48	306.95
13	233.69	284.2	299.04
14	215.64	258.32	265.91
15	302.94	344.07	359.41
16	199.47	239.36	240.48
17	223.76	258.76	262.31
18	290.75	362.31	369.36
19	331.27	382.59	399.32
20	410.78	479.62	498.57
21	467.84	574.89	579.38
22	163.38	199.23	205.6
23	509.64	578.94	595.24
24	280.51	320.97	327.47
25	260.72	296.37	305.42
26	305.94	349.62	375.15
27	104.43	129.63	134.9
28	333.43	401.29	414.85
29	244.28	295.86	295.95
30	390.13	444.82	459.26
31	183.96	206.22	207.85
32	317.58	369.34	375.27
33	348.56	396.64	400.05
34	321.54	388.64	392.64
35	266.54	307.77	324.85

CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL Nº: 0207-21A-11E
 January, 2022

E. Firmness of facial skin by Cutometer®

t= 0																	
Result	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	V14	V15	V16	V17
R0	0.085	0.049	0.091	0.079	0.037	0.098	0.086	0.058	0.053	0.102	0.034	0.053	0.1	0.11	0.049	0.053	0.087

V18	V19	V20	V21	V22	V23	V24	V25	V26	V27	V28	V29	V30	V31	V32	V33	V34	V35
0.073	0.096	0.066	0.066	0.102	0.07	0.075	0.079	0.096	0.093	0.089	0.089	0.106	0.086	0.043	0.077	0.099	0.045

t= 4 weeks																	
Result	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	V14	V15	V16	V17
R0	0.054	0.042	0.08	0.067	0.031	0.083	0.07	0.046	0.044	0.084	0.028	0.042	0.077	0.092	0.038	0.045	0.074

V18	V19	V20	V21	V22	V23	V24	V25	V26	V27	V28	V29	V30	V31	V32	V33	V34	V35
0.059	0.081	0.054	0.053	0.084	0.055	0.057	0.04	0.082	0.078	0.072	0.067	0.089	0.065	0.034	0.058	0.076	0.035

t= 12 weeks																	
Result	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	V14	V15	V16	V17
R0	0.047	0.038	0.078	0.06	0.028	0.068	0.059	0.04	0.038	0.069	0.023	0.039	0.069	0.079	0.038	0.04	0.071

V18	V19	V20	V21	V22	V23	V24	V25	V26	V27	V28	V29	V30	V31	V32	V33	V34	V35
0.048	0.074	0.048	0.049	0.069	0.048	0.045	0.04	0.078	0.07	0.07	0.056	0.076	0.061	0.031	0.054	0.073	0.03

CLINICAL EVALUATION OF THE EFFICACY OF
 IMAGE MD RESTORING POWER C SERUM
 SUMMARY PROTOCOL N°: 0207-21A-11E
 January, 2022

F. Elasticity of facial skin by Cutometer®

t= 0																	
Result	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	V14	V15	V16	V17
R7	0.703	0.725	0.738	0.801	0.71	0.757	0.804	0.703	0.727	0.791	0.723	0.738	0.745	0.81	0.714	0.797	0.671

V18	V19	V20	V21	V22	V23	V24	V25	V26	V27	V28	V29	V30	V31	V32	V33	V34	V35
0.738	0.636	0.7	0.78	0.755	0.802	0.677	0.734	0.7	0.762	0.837	0.71	0.652	0.708	0.708	0.727	0.71	0.829

t= 4 weeks																	
Result	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	V14	V15	V16	V17
R7	0.815	0.833	0.824	0.897	0.819	0.848	0.9	0.782	0.813	0.882	0.813	0.861	0.867	0.931	0.811	0.889	0.757

V18	V19	V20	V21	V22	V23	V24	V25	V26	V27	V28	V29	V30	V31	V32	V33	V34	V35
0.831	0.765	0.775	0.78	0.868	0.886	0.76	0.825	0.839	0.868	0.879	0.788	0.779	0.809	0.84	0.815	0.8	0.911

t= 12 weeks																	
Result	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	V14	V15	V16	V17
R7	0.844	0.895	0.91	0.981	0.944	0.895	0.964	0.802	0.879	0.972	0.893	0.928	0.935	0.967	0.862	0.894	0.789

V18	V19	V20	V21	V22	V23	V24	V25	V26	V27	V28	V29	V30	V31	V32	V33	V34	V35
0.883	0.819	0.833	0.812	0.897	0.899	0.797	0.874	0.875	0.893	0.916	0.863	0.799	0.853	0.892	0.881	0.898	0.967

APPENDIX C - REFERENCES

- Makki S, Barbenel JC, Agache P, A quantitative method for the assessment of microtopography of human skin. *Acta Derma Venerol* (Stockh) 1979; 59: 258-91.
- Aubert L, Brun A, Grollier JF et al, A method to show the influence of cosmetic products on the cutaneous microrelief. *Cosmet Technol Sci* 1982; 3:256-70
- Corcuff P, de Rigal J, Léveque JL et al, Skin Relief and aging. *J Soc Cosmet Chem* 1983; 34:177-90.
- Barton SP, Marshall TJ, Marks R, A novel method for assessing skin surface topography. *Bioeng Skin* 1989, 3; 93-107
- Corcuff P, Chatenay F, Brun A, Evaluation of anti-wrinkle effects on humans. *Int J Cosmet Sci* 1985; 7:17-26
- Lévenque JL, Physical methods to measure the efficiency of cosmetics in humans. *Cosmet Toiletries* 1984; 99:43-51
- Aubert L, Anthoine P, de Rigal J et al, An in vivo assessment of the biomechanical properties of human skin modification under the influence of cosmetic products. *Int J Cosmet Sci* 1985; 7:51-9
- Frosch P.J., Kurte A., Pilz B. (1993). Efficacy of skin barrier creams (III): The repetitive irritation test (RIT) in humans. *Contact Dermatitis* 29, 113-118.

Independent clinical testing laboratory: CLAIM